Low Ferritin as a Cancer Marker: What You Need to Know

Low ferritin is not a cancer marker in the way tumor-specific blood tests are, but it is one of the most reliable indirect signals that something in the gastrointestinal tract deserves investigation. Iron deficiency is the most common sign outside the gut of colonic neoplasia, including colorectal cancer, and ferritin is the standard blood test used to detect depleted iron stores.¹ The relationship between low ferritin and cancer is indirect but clinically serious, and the details matter more than the headline.

How Ferritin Connects to Cancer

Ferritin is a protein that stores iron in a form your body can use safely. A blood test measuring serum ferritin is the most common way to estimate how much iron you have in reserve.² When a tumor grows in the colon or elsewhere in the digestive tract, it often bleeds slowly into the gut. You lose small amounts of blood day after day without noticing, and over weeks or months your iron stores drain. Your ferritin drops. Eventually you may become anemic, but the ferritin decline can show up well before anemia does on a standard blood count.

This is why clinicians treat unexplained low ferritin as a red flag that needs to be run down, particularly in people who don’t have an obvious reason for iron loss. The ferritin result doesn’t tell you whether cancer is present. What it does is tell you that your body is losing iron faster than it can replace it, and one of the causes that needs to be ruled out is a bleeding lesion in the GI tract.

The Numbers Behind the Signal

One study of patients being evaluated for involuntary weight loss found that a ferritin level above 100 mcg/L had a sensitivity of 93% for ruling out colon cancer, with a negative predictive value of 99%. In practical terms, if your ferritin was above that threshold, colon cancer was extremely unlikely to be the explanation. Below 100, the test couldn’t reliably exclude it.³ The same study found that the rule didn’t hold as well for gastric or rectal cancers, where false negatives occurred. So the 100 mcg/L threshold is useful for colon cancer specifically, not for every GI malignancy.

Meanwhile, diagnosing iron deficiency itself depends on what cutoff your doctor uses. Guidelines and expert panels have recommended ferritin thresholds of 15, 30, or 45 ng/mL for identifying iron deficiency in the general adult population, and the choice of cutoff dramatically changes how many people get diagnosed.⁴ Using 15 ng/mL as the line catches only the most depleted patients. Using 45 ng/mL captures a much broader group. This matters because if your doctor uses a conservative cutoff, your iron deficiency could go unrecognized and the investigation that might find an underlying cause, including cancer, never gets triggered.

Why Inflammation Complicates the Picture

Ferritin has a frustrating quirk as a diagnostic tool: inflammation drives it up. If your body is fighting an infection, dealing with a chronic inflammatory condition, or even responding to the cancer itself, ferritin can rise regardless of how much iron you actually have stored. This means a “normal” ferritin result in someone with active inflammation could be masking genuine iron deficiency underneath.²

To deal with this, clinicians often check C-reactive protein (CRP) alongside ferritin. If CRP is elevated, the ferritin number can’t be taken at face value. Some guidelines recommend adjusting the ferritin cutoff upward when inflammation is present. For instance, one approach used in pediatric research defined iron depletion as ferritin below 15 mcg/L when CRP was normal, but below 50 mcg/L when CRP was elevated.⁵ The principle applies broadly: a ferritin level that looks reassuring in a healthy person may actually be low for someone whose body is inflamed.

Who Needs Investigation

Current clinical thinking divides people with unexplained iron deficiency into risk tiers. The strongest recommendation for endoscopic evaluation, meaning both an upper endoscopy and a colonoscopy, applies to men and postmenopausal women. In these groups, menstrual blood loss isn’t an explanation, so any significant iron deficiency raises the probability that something in the GI tract is responsible.¹

A large study of U.S. veterans with new-onset iron deficiency anemia found that the odds of GI cancer were about four and a half times higher in those with iron deficiency anemia compared to those without it.⁶ The risk was not evenly distributed by sex: within one year, about 1.2% of men with new-onset iron deficiency anemia were diagnosed with a GI cancer, compared with 0.13% of women.⁷ That gap partly reflects the fact that premenopausal women have a common alternative explanation for iron loss.

For premenopausal women, the decision to scope is more nuanced. Endoscopy is conditionally recommended rather than automatic. Research has identified certain red flags that raise the likelihood of finding a GI lesion in this group: a positive fecal occult blood test, hemoglobin below 10 g/dL, and abdominal symptoms.⁸ Without those features, the yield of endoscopy in younger women is lower, and menstrual loss remains the more probable explanation.

That said, with early-onset colorectal cancer on the rise in people under 50, the threshold for investigation may need to shift. Clinicians are increasingly aware that dismissing iron deficiency in younger patients as “probably dietary” or “probably menstrual” can miss cancers that would have been caught earlier with a scope.

Iron Deficiency Without Anemia Still Warrants Attention

One common misconception is that iron deficiency only matters once it progresses to full-blown anemia, meaning your hemoglobin drops below the normal range. Research suggests that’s wrong. A retrospective study in fast-track colorectal clinics found that patients with iron deficiency, based on low ferritin and other iron markers, were more likely to have colorectal cancer regardless of whether they were anemic.⁹ The authors argued that non-anemic iron deficiency should be investigated with the same urgency as iron deficiency anemia in the context of colorectal cancer screening.

A Western Australian cohort study put some numbers to this. Among patients with iron deficiency anemia, about 8.8% had a GI malignancy found on endoscopy. Among those who were iron deficient but not yet anemic, the rate was 1.2%.¹⁰ The rate was much lower in the non-anemic group, but 1.2% is not zero, and those are cancers that would go undetected if clinicians waited for anemia to develop before investigating. The takeaway is that isolated low ferritin, even with a normal hemoglobin, deserves a clinical conversation about whether further workup makes sense.

The Cost of Delayed Investigation

One of the frustrating realities of the ferritin-cancer connection is how often the signal gets missed or deprioritized. A retrospective study of colorectal cancer patients who initially presented with iron deficiency anemia found that only about 35% were referred to a specialty where the anemia would prompt a GI investigation. Nearly 45% had no recorded referral at all, or were referred to a specialty unrelated to their anemia or the GI tract.¹¹

The delays were substantial. Patients who were referred to a relevant surgical specialty had a median time to cancer diagnosis of about two and a half months. Those referred to hematology, where the focus is on the blood abnormality rather than its cause in the gut, waited a median of nearly 32 months. That’s almost three years of a cancer growing while the symptom that flagged it was being managed as a blood disorder rather than investigated as a GI problem.

Similar patterns appear in the veteran population. Among younger veterans with new-onset iron deficiency anemia, fewer than 10% underwent the recommended bidirectional endoscopy within a year. Men were far more likely to be scoped than women, even after accounting for other factors.⁷ The underuse of endoscopy in women is especially concerning given that the conditional recommendation for premenopausal women can be interpreted too conservatively, leading to genuine cancers being overlooked.

Why Tumors Are Hungry for Iron

The connection between cancer and iron deficiency isn’t just about bleeding. Cancer cells have an outsized appetite for iron. Rapidly dividing cells need iron as a cofactor for DNA synthesis and for the mitochondrial machinery that produces energy. To get more of it, tumor cells ramp up the pathways that pull iron into the cell, including overexpressing a receptor called transferrin receptor 1.¹² This receptor has been found at abnormally high levels across a wide range of cancer types.

This metabolic reprogramming effectively means the tumor is competing with the rest of your body for available iron. The tumor upregulates iron uptake and storage pathways to fuel its growth, which can contribute to the depletion of your systemic iron stores.¹³ For GI cancers, the dominant mechanism of iron loss is still chronic bleeding from the tumor surface into the gut. But the tumor’s iron greed adds another drain on top of that, and in cancers that don’t bleed into an accessible space, it may be the primary explanation for iron deficiency.

Not Every Low Ferritin Means Cancer

It’s worth being explicit: most people with low ferritin do not have cancer. Iron deficiency is extremely common worldwide, and the vast majority of cases are explained by dietary insufficiency, menstrual loss, pregnancy, blood donation, or conditions that impair iron absorption. Celiac disease, for instance, damages the lining of the small intestine and can cause significant malabsorption of iron. Helicobacter pylori infection, the bacterium behind most stomach ulcers, is another well-documented cause of iron deficiency anemia.¹⁴ Clinical guidelines actually recommend taking duodenal biopsies to rule out celiac disease when investigating iron deficiency anemia, and H. pylori testing is part of the standard workup in many cases.

The clinical challenge is distinguishing benign causes from sinister ones without over-investigating every person who has a low ferritin. Context matters enormously. A 25-year-old woman with heavy periods and a ferritin of 8 ng/mL has a very different risk profile from a 60-year-old man with a ferritin of 8 ng/mL and no obvious source of blood loss. The first scenario likely needs iron supplementation and menstrual management. The second scenario needs a colonoscopy and an upper endoscopy, ideally without delay.

Newer Tools for Deciding Who Gets Scoped

Colonoscopy capacity is limited, and not every person with low ferritin can or should get one immediately. Researchers have been working on ways to triage patients more effectively, and one of the more promising tools is the fecal immunochemical test, or FIT. This is a stool test that detects tiny amounts of blood in the gut. A systematic review and meta-analysis found that FIT shows high sensitivity for advanced colorectal neoplasia in patients with iron deficiency, making it a useful way to prioritize who gets a colonoscopy first when resources are stretched.¹⁵

Building on this, researchers have developed combined models that incorporate FIT results along with other clinical variables to predict which iron-deficient patients are most likely to have colorectal cancer. One such model showed it could substantially reduce the number of unnecessary colonoscopies while still catching the cancers that needed to be found.¹⁶ This kind of approach is especially relevant as healthcare systems grapple with growing demand for endoscopy and limited slots. If a cheap stool test can safely sort patients into urgent and less-urgent categories, that means faster diagnosis for the people who need it most.

FIT is not a replacement for endoscopy in high-risk groups. Men and postmenopausal women with unexplained iron deficiency should still generally be scoped. But in settings where wait times are long, or in populations where the pre-test probability of cancer is lower, a negative FIT result combined with a clinical risk model may provide enough reassurance to safely defer a colonoscopy while monitoring the patient.

Iron Deficiency in Cancers Beyond the Gut

While the strongest evidence links low ferritin to GI malignancies, iron deficiency shows up in other cancer contexts as well. A retrospective study of gynecological cancer patients undergoing treatment found that among those who developed chemotherapy-induced anemia, about three-quarters had iron deficiency of some type.¹⁷ Most of these cases involved what’s called functional iron deficiency, where the body has iron stored but can’t mobilize it effectively because of inflammation or the disease process itself. Only a small fraction had truly empty iron stores.

This distinction matters. In the setting of known cancer, a low ferritin may represent actual depletion from chronic blood loss or poor nutrition, or it may reflect the body’s inability to use the iron it has. The treatment approach differs: true iron deficiency responds to supplementation, while functional iron deficiency often requires addressing the underlying inflammation or using intravenous iron that bypasses the usual absorption and mobilization pathways. For patients already diagnosed with cancer, ferritin is less about detection and more about managing the anemia that worsens fatigue and can delay treatment cycles.

The Evolving Role of Ferritin in Cancer Research

Ferritin has been part of the clinical toolkit since the 1970s, when it was first developed as a lab test.¹⁸ For decades it was treated mainly as an indicator of iron stores and nothing more. That view has expanded considerably. Researchers are now investigating ferritin as a prognostic marker across a range of cancers, not just as a passive indicator of iron depletion but as a molecule whose levels may reflect tumor behavior, inflammation, and the body’s metabolic response to malignancy.¹⁹

Interestingly, this research cuts both ways. While low ferritin points to iron depletion and raises the alarm for GI bleeding, very high ferritin can also be a cancer signal, because some tumors release ferritin directly or trigger enough systemic inflammation to push ferritin levels far above normal. This means ferritin is not a simple “lower is worse” marker. It sits at a crossroads of iron metabolism and inflammation, and its interpretation depends entirely on the clinical context. A ferritin of 10 in a man with no explanation might lead to a cancer diagnosis via colonoscopy. A ferritin of 1,500 in someone with unexplained fevers might lead to a cancer diagnosis via a very different workup. The protein is the same; the stories it tells are completely different.